Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | CCR6 | P51684 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860311 | 0.94 | EPHX1 (0.78) | ALDH1A1MAPTLMNAEPHX1NPC1 | |
| SCHEMBL3055480 | 0.91 | ALDH1A1 (0.81) | ALDH1A1MAPTLMNAEPHX1NPC1 | |
| SCHEMBL12767872 | 0.89 | KMT2A (0.72) | ALDH1A1MAPTLMNAEPHX1NPC1 | |
| N-(Phenylcarbamothioyl)Benzamide SCHEMBL2341910 | 0.88 | EPHX1 (1.00) | ALDH1A1EPHX1NPC1RAB9ANPSR1 | |
| SCHEMBL14096440 | 0.87 | EPHX1 (0.78) | ALDH1A1MAPTEPHX1NPC1RAB9A | |
| SCHEMBL8616503 | 0.87 | EPHX1 (0.83) | ALDH1A1LMNAEPHX1NPC1RAB9A | |
| SCHEMBL14096532 | 0.86 | KMT2A (0.72) | ALDH1A1MAPTLMNANPC1RAB9A | |
| SCHEMBL5713540 | 0.86 | EPHX1 (0.71) | ALDH1A1MAPTLMNAEPHX1NPC1 | |
| SCHEMBL31321777 | 0.85 | ALDH1A1 (0.85) | ALDH1A1EPHX1NPC1RAB9ANPSR1 | |
| SCHEMBL27451748 | 0.85 | MIF (0.83) | ALDH1A1EPHX1NPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536286-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | Siga Technologies, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| CN-101129295-B | There is the binary initiator system of good storage stability and especially suitable for acidic system | HERAEUS KULZER GMBH (DE) | 2016-02-10 | — | — | CN | disclosed |
| CN-100420678-C | Cyclization process for substituted benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | CN | disclosed |
| CN-101129295-A | 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems | HERAEUS KULZER GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1583752-B1 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-7087761-B2 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| CN-1738808-A | Cyclization process for substituted benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2006-02-22 | — | — | CN | disclosed |
| EP-1583752-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004060879-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | CBR3, CBR1, OXTR | ALDH1A1 2709/4885MAPT 4736/4885LMNA 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.